JP2020508317A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020508317A5 JP2020508317A5 JP2019545324A JP2019545324A JP2020508317A5 JP 2020508317 A5 JP2020508317 A5 JP 2020508317A5 JP 2019545324 A JP2019545324 A JP 2019545324A JP 2019545324 A JP2019545324 A JP 2019545324A JP 2020508317 A5 JP2020508317 A5 JP 2020508317A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- seq
- antibody
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022037781A JP7384949B2 (ja) | 2017-02-21 | 2022-03-11 | 肺癌の処置のための抗ｐｄ－１抗体 |
| JP2023190525A JP7656012B2 (ja) | 2017-02-21 | 2023-11-08 | 肺癌の処置のための抗ｐｄ－１抗体 |
| JP2025044340A JP2025098103A (ja) | 2017-02-21 | 2025-03-19 | 肺癌の処置のための抗ｐｄ－１抗体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762461672P | 2017-02-21 | 2017-02-21 | |
| US62/461,672 | 2017-02-21 | ||
| US201762595190P | 2017-12-06 | 2017-12-06 | |
| US62/595,190 | 2017-12-06 | ||
| PCT/US2018/018747 WO2018156494A1 (en) | 2017-02-21 | 2018-02-20 | Anti-pd-1 antibodies for treatment of lung cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022037781A Division JP7384949B2 (ja) | 2017-02-21 | 2022-03-11 | 肺癌の処置のための抗ｐｄ－１抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020508317A JP2020508317A (ja) | 2020-03-19 |
| JP2020508317A5 true JP2020508317A5 (enExample) | 2021-07-26 |
| JP7324710B2 JP7324710B2 (ja) | 2023-08-10 |
Family
ID=61628468
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019545324A Active JP7324710B2 (ja) | 2017-02-21 | 2018-02-20 | 肺癌の処置のための抗ｐｄ－１抗体 |
| JP2022037781A Active JP7384949B2 (ja) | 2017-02-21 | 2022-03-11 | 肺癌の処置のための抗ｐｄ－１抗体 |
| JP2023190525A Active JP7656012B2 (ja) | 2017-02-21 | 2023-11-08 | 肺癌の処置のための抗ｐｄ－１抗体 |
| JP2025044340A Pending JP2025098103A (ja) | 2017-02-21 | 2025-03-19 | 肺癌の処置のための抗ｐｄ－１抗体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022037781A Active JP7384949B2 (ja) | 2017-02-21 | 2022-03-11 | 肺癌の処置のための抗ｐｄ－１抗体 |
| JP2023190525A Active JP7656012B2 (ja) | 2017-02-21 | 2023-11-08 | 肺癌の処置のための抗ｐｄ－１抗体 |
| JP2025044340A Pending JP2025098103A (ja) | 2017-02-21 | 2025-03-19 | 肺癌の処置のための抗ｐｄ－１抗体 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11292842B2 (enExample) |
| EP (1) | EP3585812A1 (enExample) |
| JP (4) | JP7324710B2 (enExample) |
| KR (2) | KR20240011262A (enExample) |
| CN (2) | CN117442719A (enExample) |
| AU (2) | AU2018225102B2 (enExample) |
| CA (1) | CA3054289A1 (enExample) |
| IL (3) | IL321717A (enExample) |
| MA (1) | MA47604A (enExample) |
| MX (2) | MX2019009772A (enExample) |
| WO (1) | WO2018156494A1 (enExample) |
| ZA (1) | ZA201905051B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160053301A1 (en) | 2014-08-22 | 2016-02-25 | Clearfork Bioscience, Inc. | Methods for quantitative genetic analysis of cell free dna |
| UA124379C2 (uk) | 2015-08-11 | 2021-09-08 | Усі Байолоджікс Айрленд Лімітед | Нові антитіла проти білка pd-1 |
| TWI843168B (zh) | 2016-10-11 | 2024-05-21 | 美商艾吉納斯公司 | 抗ｌａｇ－３抗體及其使用方法 |
| CN117442719A (zh) * | 2017-02-21 | 2024-01-26 | 瑞泽恩制药公司 | 用于治疗肺癌的抗pd-1抗体 |
| US11389525B2 (en) * | 2017-10-27 | 2022-07-19 | Statens Serum Institut | Polygene influenza vaccine |
| SG11202102644XA (en) | 2018-09-19 | 2021-04-29 | Alpine Immune Sciences Inc | Methods and uses of variant cd80 fusion proteins and related constructs |
| HRP20240825T1 (hr) | 2018-11-14 | 2024-09-27 | Regeneron Pharmaceuticals, Inc. | Intralezijsko davanje pd-1 inhibitora za liječenje raka kože |
| CN113557060A (zh) * | 2019-01-21 | 2021-10-26 | 赛诺菲 | 用于晚期实体瘤癌症的治疗性rna |
| CA3137361A1 (en) * | 2019-02-28 | 2020-09-03 | Regeneron Pharmaceuticals, Inc. | Administration of pd-1 inhibitors for treating skin cancer |
| WO2020180727A1 (en) | 2019-03-06 | 2020-09-10 | Regeneron Pharmaceuticals, Inc. | Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer |
| KR20220115803A (ko) * | 2019-12-13 | 2022-08-18 | 삼성바이오에피스 주식회사 | 안정한 항-pd-1 항체 약제학적 제제 |
| CN113244385A (zh) * | 2020-02-07 | 2021-08-13 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在治疗恶性肿瘤中的用途 |
| DK4117667T3 (da) * | 2020-03-13 | 2025-02-10 | Univ Texas | Sekventiel behandling af kræft ved hjælp af 6-thio-dg og checkpointhæmmere |
| WO2023185720A1 (zh) * | 2022-03-28 | 2023-10-05 | 齐鲁制药有限公司 | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 |
| EP4598960A1 (en) * | 2022-10-05 | 2025-08-13 | Chulalongkorn University | Monoclonal antibodies against human programmed cell death protein 1 (pd-1) |
| WO2025030110A1 (en) * | 2023-08-02 | 2025-02-06 | Sensei Biotherapeutics, Inc. | Cancer therapies targeting vista as monotherapy or in combination with anti-pd1 antibody to treat cancer |
| WO2025159618A1 (ko) | 2024-01-24 | 2025-07-31 | 주식회사 엘지에너지솔루션 | 전극탭 용접장치 및 전극탭 용접방법 |
| WO2025207705A1 (en) | 2024-03-26 | 2025-10-02 | Amgen Inc. | Cancer treatments using mta-cooperative prmt5 inhibitors |
| WO2025213154A1 (en) | 2024-04-05 | 2025-10-09 | Amgen Inc. | Gastrointestinal cancer treatments using mta-cooperative prmt5 inhibitors |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| PT1210428E (pt) | 1999-08-23 | 2015-07-21 | Genetics Inst Llc | Pd-1, um recetor para b7-4 e suas utilizações |
| US7794710B2 (en) | 2001-04-20 | 2010-09-14 | Mayo Foundation For Medical Education And Research | Methods of enhancing T cell responsiveness |
| JP4511943B2 (ja) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Ｐｄ−１に対する抗体およびその使用 |
| JP4532409B2 (ja) | 2003-01-23 | 2010-08-25 | 小野薬品工業株式会社 | ヒトｐｄ−１に対し特異性を有する物質 |
| AU2006230099B2 (en) | 2005-03-25 | 2012-04-19 | Gitr, Inc. | GITR binding molecules and uses therefor |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| EP2175884B8 (en) | 2007-07-12 | 2017-02-22 | GITR, Inc. | Combination therapies employing gitr binding molecules |
| WO2009030285A1 (en) | 2007-09-07 | 2009-03-12 | Ablynx N.V. | Binding molecules with multiple binding sites, compositions comprising the same and uses thereof |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| WO2010027423A2 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
| TWI605828B (zh) | 2008-12-09 | 2017-11-21 | 建南德克公司 | 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途 |
| CN102574924A (zh) | 2009-09-03 | 2012-07-11 | 先灵公司 | 抗-gitr抗体 |
| WO2011066389A1 (en) | 2009-11-24 | 2011-06-03 | Medimmmune, Limited | Targeted binding agents against b7-h1 |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| CA2802344C (en) | 2010-06-18 | 2023-06-13 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| EP2734551B1 (en) | 2011-07-24 | 2018-01-10 | Cure Tech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
| JP6238459B2 (ja) | 2011-08-01 | 2017-11-29 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法 |
| EP2844674A1 (en) | 2012-05-04 | 2015-03-11 | Dana-Farber Cancer Institute, Inc. | Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use |
| US9889982B2 (en) | 2012-07-23 | 2018-02-13 | Silgan Dispensing Systems Corporation | Aerosol actuators, devices, and methods of making and using the same |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| WO2015030929A1 (en) | 2013-08-30 | 2015-03-05 | Ebay, Inc. | Keyword bid optimization for text ads |
| WO2015088930A1 (en) | 2013-12-10 | 2015-06-18 | Merck Sharp & Dohme Corp. | Immunohistochemical proximity assay for pd-1 positive cells and pd-ligand positive cells in tumor tissue |
| PT3083689T (pt) | 2013-12-17 | 2020-08-27 | Genentech Inc | Anticorpos anti-cd3 e métodos de utilização |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| CN106714839A (zh) * | 2014-05-15 | 2017-05-24 | 百时美施贵宝公司 | 使用抗pd‑1抗体和另一种抗癌剂的组合治疗肺癌 |
| RS61678B1 (sr) | 2014-05-28 | 2021-05-31 | Agenus Inc | Anti-gitr antitela i postupci za njihovu primenu |
| MY181896A (en) | 2014-06-06 | 2021-01-12 | Bristol Myers Squibb Co | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
| US10092645B2 (en) | 2014-06-17 | 2018-10-09 | Medimmune Limited | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy |
| WO2015196051A1 (en) | 2014-06-19 | 2015-12-23 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized programmed cell death 1 gene |
| AU2015355137A1 (en) * | 2014-12-02 | 2017-06-08 | Celgene Corporation | Combination therapies |
| EP3254110B1 (en) | 2015-02-03 | 2020-03-18 | Ventana Medical Systems, Inc. | Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1) |
| CN114702586A (zh) | 2015-03-13 | 2022-07-05 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| ES2813580T3 (es) * | 2015-04-17 | 2021-03-24 | Bristol Myers Squibb Co | Composiciones que comprenden una combinación de ipilimumab y nivolumab |
| ES2835866T5 (es) * | 2015-05-12 | 2024-12-02 | Hoffmann La Roche | Procedimientos terapéuticos y de diagnóstico para el cáncer |
| WO2016191751A1 (en) * | 2015-05-28 | 2016-12-01 | Bristol-Myers Squibb Company | Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody |
| KR20180111870A (ko) | 2016-02-25 | 2018-10-11 | 셀 메디카 스위처란트 아게 | Pd-l1에 대한 결합 성분 |
| JP7105235B2 (ja) | 2016-12-01 | 2022-07-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 免疫ｐｅｔイメージングのための放射性標識された抗ｐｄ－ｌ１抗体 |
| CN117442719A (zh) * | 2017-02-21 | 2024-01-26 | 瑞泽恩制药公司 | 用于治疗肺癌的抗pd-1抗体 |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| US20240270849A1 (en) * | 2022-10-03 | 2024-08-15 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer with bispecific egfr xcd28 antibodies alone or in combination with anti-pd-1 antibodies |
-
2018
- 2018-02-20 CN CN202311425489.2A patent/CN117442719A/zh active Pending
- 2018-02-20 WO PCT/US2018/018747 patent/WO2018156494A1/en not_active Ceased
- 2018-02-20 IL IL321717A patent/IL321717A/en unknown
- 2018-02-20 IL IL268479A patent/IL268479B2/en unknown
- 2018-02-20 JP JP2019545324A patent/JP7324710B2/ja active Active
- 2018-02-20 EP EP18711195.0A patent/EP3585812A1/en active Pending
- 2018-02-20 CA CA3054289A patent/CA3054289A1/en active Pending
- 2018-02-20 MX MX2019009772A patent/MX2019009772A/es unknown
- 2018-02-20 KR KR1020247001790A patent/KR20240011262A/ko active Pending
- 2018-02-20 CN CN201880026252.8A patent/CN110536905B/zh active Active
- 2018-02-20 US US16/486,688 patent/US11292842B2/en active Active
- 2018-02-20 AU AU2018225102A patent/AU2018225102B2/en active Active
- 2018-02-20 MA MA047604A patent/MA47604A/fr unknown
- 2018-02-20 KR KR1020197027687A patent/KR102628557B1/ko active Active
-
2019
- 2019-07-31 ZA ZA2019/05051A patent/ZA201905051B/en unknown
- 2019-08-15 MX MX2024000780A patent/MX2024000780A/es unknown
-
2022
- 2022-02-28 US US17/652,709 patent/US11926668B2/en active Active
- 2022-03-11 JP JP2022037781A patent/JP7384949B2/ja active Active
-
2023
- 2023-11-08 JP JP2023190525A patent/JP7656012B2/ja active Active
- 2023-11-23 IL IL308805A patent/IL308805B2/en unknown
-
2024
- 2024-01-29 US US18/425,027 patent/US20240209090A1/en active Pending
-
2025
- 2025-02-13 AU AU2025201018A patent/AU2025201018A1/en active Pending
- 2025-03-19 JP JP2025044340A patent/JP2025098103A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020508317A5 (enExample) | ||
| IL321717A (en) | Anti-PD-1 antibodies for the treatment of lung cancer | |
| KR102333658B1 (ko) | 비-소세포 폐암을 치료하기 위한 항-ｂ7-ｈ1 및 항-ｃｔｌａ-4 항체 | |
| JP2022078265A5 (enExample) | ||
| JP2022050618A5 (enExample) | ||
| JP2019515008A5 (enExample) | ||
| IL318482A (en) | Pd-1 inhibitor for use in a method of treating skin cancer | |
| JP2016520082A5 (enExample) | ||
| CN111132696B (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| FI3810281T3 (fi) | Menetelmiä syövän hoitamiseksi bispesifisillä anti-CD3XMUC16-vasta-aineilla ja anti-PD-1-vasta-aineilla | |
| JP7491220B2 (ja) | 免疫チェックポイント阻害薬およびｆｏｌｆｉｒｉｎｏｘ療法との併用によるがん治療 | |
| EP3347054A1 (en) | Dosing regimens for anti-tf-antibody drug-conjugates | |
| CN108350080A (zh) | 用于癌症的联合疗法 | |
| WO2017205216A1 (en) | Combination of pembrolizumab and abemaciclib for the treatment of cancer | |
| CN111166878B (zh) | 靶向肿瘤抗原的抗体与iNKT细胞的组合的制备方法与用途 | |
| CN109663130B (zh) | Pd-1抗体和mek抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JPWO2020232019A5 (enExample) | ||
| JPWO2020223702A5 (enExample) | ||
| CN118871128A (zh) | 抗tim-3抗体与抗pd-l1抗体的药物组合 | |
| WO2024026019A1 (en) | Methods for treating chronic myelomonocytic leukemia with anti-ilt3 antibodies | |
| Hwang et al. | Emerging egfr-targeted therapy in head and neck cancer: A review | |
| TWI814752B (zh) | 免疫治療劑、核苷類抗代謝物和鉑類聯合在製備治療腫瘤的藥物中的用途 | |
| KR20200105825A (ko) | 삼중 음성 유방암의 치료를 위한 ｐｄ－１ 항체 및 아파티닙의 조합 치료의 용도 | |
| WO2024041652A1 (en) | Methods of cancer treatment | |
| CN119607196A (zh) | 抗lag-3抗体与抗pd-1抗体的应用 |